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MaMany see the broadened eligibility of cardiac rehabilitation (CR) to include heart failure with reduced ejection fraction
(HFrEF) as a likely catalyst to high CR enrollment and improved care. However, such expectation contrasts with the
reality that CR enrollment of eligible coronary heart disease patients has remained low for decades. In this review,
entrenched obstacles impeding utilization of CR are considered, particularly in relation to potential HFrEF management.
The strengths and limitations of the HF-ACTION (Heart Failure–A Controlled Trial Investigating Outcomes of Exercise
Training) trial to advance precepts of CR are considered, as well as gaps that this trial failed to address, such as the
utility of CR for patients with heart failure with preserved ejection fraction and the conundrum of poor patient
adherence. (J Am Coll Cardiol 2015;65:2652–9) © 2015 by the American College of Cardiology Foundation.T he recent decision by the U.S. Center forMedicare Services (CMS) to extend cardiacrehabilitation (CR) coverage to patients with
heart failure with reduced ejection fraction (HFrEF)
(1) caps years of cumulative research showing the
beneﬁts of exercise training, lifestyle modiﬁcations,
medication adherence, education, and other CR ele-
ments to moderate HFrEF pathophysiology and
improve clinical outcomes (2–4). Many healthcare
experts anticipate that the new CMS eligibility will
translate rapidly into CR enrollment by HFrEF pa-
tients (5). However, CMS coverage of CR for coronary
heart disease (CHD) is longstanding and has beenm the *Geriatric Research, Education, and Clinical Center and Division of
d the Veterans Administration Pittsburgh Healthcare System, University o
Medicine, Divisions of Cardiology and Geriatric Medicine, Auburn Universi
Medicine, Harrington Heart & Vascular Institute, University Hospitals Hea
Medicine, Cleveland, Ohio; xUniversity Hospitals Health System, Case
veland, Ohio; and the kDepartment of Medicine, Division of Cardiovasc
mingham, Alabama. Dr. Forman is supported in part from NIA grant P30
eived research support from Amgen, Bayer Healthcare, Janssen Pharma
visory boards for Amgen and Eli Lilly. All other authors have reported that t
s paper to disclose. The views expressed in this paper by the American
scular Disease Section do not necessarily reﬂect the views of JACC or the
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
nuscript received March 3, 2015; revised manuscript received April 23, 20reinforced over time by data demonstrating improved
outcomes among CHD patients who attended CR
(i.e., consistently beyond the evolving standards of
contemporary care), yet underenrollment has per-
sisted (6). Therefore, irrespective of CMS eligibility,
CR implementation for HFrEF patients may consti-
tute more of a challenge than many presume.
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = coronary heart disease
CMS = Center for Medicare
Services
CPX = cardiopulmonary
exercise testing
CR = cardiac rehabilitation
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
LVAD = left ventricular assist
devices
MI = myocardial infarction
VO2 = oxygen uptake
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2653prolonged bed rest to standards of earlier activity
and greater emphasis on self-care (6). Subsequently,
evolving insights regarding atherosclerosis initiation,
progression, and regression indicated that CR not
only had potential to reduce morbidity and mortality
by moderating the sequelae of sedentary behaviors
(e.g., pulmonary emboli, deconditioning), but that
it also could more fundamentally moderate the
pathophysiology of atherosclerosis (6). Overall, the
rationale for CR for acute coronary syndromes,
revascularization, and/or chronic CHD has progressed
over time, but utilization has persistently lagged (6).
The inherent weakness of CR research has
contributed to poor CR utilization for CHD. CR bene-
ﬁts were originally based predominantly on small
single-site investigations (7) that tended to enroll
mostly middle-aged, ethnically homogeneous males
who were also usually better educated and motivated
than patients who did not attend CR. Given the
limited statistical power of such studies, assessments
of CR mortality beneﬁts relied on meta-analyses (8),
and were subject to the inherent limitations of such
secondary analyses.
Nonetheless, recent analyses of large contempo-
rary databases corroborate CR beneﬁts for patients
across spectra of different ages, sexes, and thera-
pies (including both revascularization and adjunctive
treatments). The Rochester Epidemiologic Project
(9) showed that CR beneﬁts on mortality and recur-
rent MI were greater as cardiac care advanced over
time. Suaya et al. (10) used propensity-based match-
ing, regression modeling, and instrumental variables
to show mortality reductions in all demographic and
clinical subgroups, including patients with acute MI
and revascularization procedures.
IS CR FOR HFrEF DIFFERENT?
Evolving over 20 years, multiple smaller HFrEF exer-
cise training trials demonstrated wide-ranging physi-
ological and clinical beneﬁts, including improved
exercise capacity, favorable cardiac remodeling, and
improved autonomic balance (11). However, most of
the formative trials were completed at single centers
with implicit selection bias akin to the CR for CHD
literature. Moreover, skepticism regarding the utility
of exercise therapy for HFrEF was magniﬁed by safety
concerns. In comparison to patients with CHD, HFrEF
patients tend to be more prone to arrhythmia, hemo-
dynamic instability, and ﬂuid overload, and are often
older and frailer, and have more comorbidities. Con-
cerns were particularly intensiﬁed when 1 exercise
trial reported adverse remodeling in patients who
had sustained recent anterior Q-wave MIs (12).Remarkably, that study engendered wide-
spread apprehension regarding exercise
training for heart failure (HF), despite its
small size (only 13 patients) and that only 3
patients had HF. Proponents of exercise
training for HFrEF countered with assertions
regarding the predominant safety of exercise
training in multiple other studies (13).
Amid such contention, the HF-ACTION
(Heart Failure: A Controlled Trial Investi-
gating Outcomes of Exercise Training) trial
was designed to deﬁnitively assess the safety
and efﬁcacy of exercise training for HF, and
to potentially justify changes in practice
standards (4). The National Heart, Lung,
and Blood Institute made a forward-thinking
decision to invest appreciably in the pro-
mise of therapeutic exercise. The HF-ACTION
trial was large (targeting 3,000 patients), resource-
intensive, and expensive (approximately $40 million)
(personal communication, C. M. O’Connor, January
2015).
WHAT THE HF-ACTION TRIAL ACCOMPLISHED
The HF-ACTION trial assessed the safety and efﬁcacy
of exercise training for medically stable patients with
HFrEF (left ventricular ejection fraction #35%, New
York Heart Association functional class II to IV).
Notable features included the large and diverse study
population, the randomized controlled trial design,
and the requirement for optimal medical manage-
ment, including pharmacologic therapy with an
angiotensin-converting enzyme inhibitor and beta-
blockers. Approximately 40% of patients (exercise
group and controls) had implanted cardiac de-
ﬁbrillators, and 18% had biventricular pacing. Given
such comprehensive baseline care, the trial’s capacity
to assess additive beneﬁts of a CR-like intervention
were intended to be unambiguous.
The HF-ACTION exercise group began with 36
supervised training sessions for 30 min of exercise
3 times per week, with an individualized exercise
prescription on the basis of cardiopulmonary exercise
testing (CPX). Halfway through this training period,
patients received, at no cost, a home treadmill or
stationary bicycle and a heart-rate monitor for per-
sonal use. They were instructed to exercise 5 times
per week at moderate intensity for 40 min. In
contrast, the usual-care group was only given in-
structions regarding the beneﬁts of exercise training
at moderate intensity for 30 min per day, as re-
commended by the existing American College of Car-
diology/American Heart Association guidelines (14).
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educational resources, adherence recommendations,
and close supportive care from the research team.
This support may have been more effectual in the
exercise group because these elements were implic-
itly reinforced by integration with the regular exercise
sessions (15).
Only 2,331 of the 3,000 HFrEF subjects originally
targeted for the study were enrolled into the HF-
ACTION trial. Power calculations for the trial were
reassessed after approximately 2,000 patients had
been enrolled, and, on the basis of a higher event rate
than originally anticipated, only 2,300 patients were
deemed necessary for 90% statistical power. Corre-
spondingly, the target sample size was reduced (4).
The HF-ACTION trial’s composite primary
endpoint was all-cause mortality or all-cause hospital
stay. After a median follow-up of 30 months, there
was a nonsigniﬁcant reduction in the primary com-
bined endpoint (hazard ratio: 0.93; 95% conﬁdence
interval: 0.84 to 1.02; p ¼ 0.13). However, after
adjusting for baseline characteristics strongly pre-
dictive of these clinical outcomes (duration of the
cardiopulmonary exercise test; left ventricular ejec-
tion fraction; Beck Depression Inventory II score;
history of atrial ﬁbrillation) the primary endpoint was
signiﬁcant (hazard ratio: 0.89; 95% conﬁdence inter-
val: 0.81 to 0.99; p ¼ 0.03). The secondary endpoint of
cardiovascular mortality or HF hospitalization was
also signiﬁcantly improved by the exercise training
intervention after adjusting for prognostic baseline
characteristics (hazard ratio: 0.85; 95% conﬁdence
interval: 0.74 to 0.99; p ¼ 0.03) (4).
HALF FULL OR HALF EMPTY?
Some interpret the HF-ACTION trial as an important
success, as it demonstrated the safety of exercise
training in a large, diverse HFrEF population, with
beneﬁts that extended beyond optimal pharmaco-
logical and device therapies. Exercise training
was associated with an 11% reduction in all-cause
mortality/hospitalizations, as well as a 15% reduc-
tion in cardiovascular mortality/HF hospitalizations.
In addition, a substudy demonstrated improved
quality of life using the Kansas City Cardiomyopathy
Questionnaire (16).
In a subsequent analysis, Keteyian et al. (17)
demonstrated that patients who achieved increased
exercise volume during the HF-ACTION trial had rela-
tively better outcomes, supporting the concept of a
dose–response relationship. Exercise volume was a
signiﬁcant (p ¼ 0.001) predictor of reduced mortality
(all cause or cardiac) or hospitalization (all cause or HF.Moderate exercise volumes of 3 to 7 metabolic equiva-
lent hours per week were associated with reductions
in risk exceeding 30%. Swank et al. (18) reported simi-
larly improved outcomes in the HF-ACTION trial pa-
tients who achieved increased peak oxygen uptake
(VO2) over the course of the exercise-training program.
Others regard the HF-ACTION trial more critically
(19). Some impugn the conclusions because statisti-
cally signiﬁcant beneﬁts of exercise training were
only evident after statistical methods adjusted for
predictive factors for the same outcomes. Others
criticize the HF-ACTION trial’s need to extend en-
rollment to 79 study sites in the United States and
abroad in order to achieve enrollment goals, inferring
that exercise training is inherently problematic,
especially considering the reduction in enrollment
targets more than halfway through the trial. Similarly,
despite multiple methods to reinforce adherence,
only approximately 30% of those in the HF-ACTION
trial’s exercise arm exercised at or above the target
number of minutes per week. Furthermore, the
demonstration of greater mortality beneﬁts in HFrEF
patients who were able to sustain exercise therapy
implicitly calls attention to the erosion of the treat-
ment effect targeted in the original trial design by
poor exercise adherence.
Notably, a related HF-ACTION trial analysis
showed that poor adherence was not predictable at
enrollment using standard assessment criteria (20).
However, it is also noteworthy that while female sex
and nonwhite race are commonly associated with
poor CR enrollment and high attrition, women and
self-identiﬁed black patients in the HF-ACTION trial
achieved signiﬁcant exercise training beneﬁts (21,22).
Both women and black patients had lower peak VO2
and 6-min walk distance at baseline than male
and white patients, respectively, but training effects
and clinical beneﬁts were preserved. Risk reduction
of the primary endpoint (all-cause mortality and
hospitalization) was greater in women than in
men, with a signiﬁcant treatment by sex interaction
(p ¼ 0.027) (21).
THE HF-ACTION TRIAL AND CR:
AN IMPORTANT ADVANCE,
BUT WITH GAPS TO FILL
The HF-ACTION trial provides a greater rationale to
justify CMS ﬁnancing for CR for HFrEF than any
prior single study has done to justify CR for other
diagnoses, yet still leaves residual concerns and
questions, particularly due to its limited enrollment
and suboptimal adherence. Home-based exercise
adherence by the exercise group fell from a weekly
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months 4 to 6 to only 50 min (interquartile range:
0 to 140min) during year 3 (4). Many interpret the poor
enrollment and adherence as supporting a mandate
to consider novel CR strategies to better implement
and sustain wellness behaviors (e.g., home-based CR,
mobile device CR, or other technological options in
the burgeoning ﬁeld of telehealth) (6).
Some critics also question the basic assumption
that the HF-ACTION trial can be associated with
contemporary CR because HFrEF may differ from CR’s
primary orientation to CHD (23). The distinctive risks
and needs of HFrEF patients may necessitate new
CR program designs and technologies. The expertise
of CR personnel may also need to be modiﬁed to
meet the needs of a different patient population (5).
More practically, the HF-ACTION trial focused
primarily on the safety and rudimentary efﬁcacy of
aerobic exercise for HFrEF, but avoided many other
challenges germane to contemporary HFrEF man-
agement. Participants could not be enrolled until
6 weeks after hospitalization for decompensated
HF; thus, the safety and potential efﬁcacy of earlier
enrollment in CR to decrease HFrEF readmissions
are unknown. Similarly, the HF-ACTION trial utilized
CPX and 6-min walk testing as metrics by which to
assess exercise training efﬁcacy and as standards to
ensure clinical safety and stability prior to exercise
training. While this builds on a tradition of formalized
functional assessments before CR, many see such
stringencies as inherent barriers to exercise training,
especially for patients who have been presumably
stabilized on medications, implanted cardiac de-
ﬁbrillators, and other provisions of care (24). It
is possible that the poor enrollment into the
HF-ACTION trial was exacerbated by the protocol’s
rigid requirements for CPX, walking tests, and site-
based exercise training (and the inherent logistic
difﬁculties). Options to use exercise assessments and
exercise supervision more selectively, to potentially
make exercise training more accessible and uncom-
plicated to relatively more stable subsets of HFrEF
patients, were not considered or assessed.
The HF-ACTION trial also enrolled few adults
>75 years of age, and failed to address advanced
age complexities germane to HFrEF care (e.g., mul-
timorbidity, polypharmacy, frailty). Likewise, the
HF-ACTION trial utilized only 1 approach to exercise
(moderate intensity, continuous aerobic exercise),
but did not incorporate other modalities (e.g.,
strength and inspiratory training) and intensities
(e.g., high-intensity interval training) that might
better suit different clinical contexts (e.g., frailty,
obesity) and/or patient populations (e.g., women,elderly). HF with preserved ejection fraction (HFpEF),
the dominant form of HF among older adults (25),
was entirely omitted. Exercise training for HFrEF
patients with left ventricular assist devices (LVADs),
an increasingly common HFrEF management option,
was also not included.
THE NEED FOR MORE RESEARCH
CR FOR HFpEF. Reports show an already large and
growing prevalence of HFpEF (25,26), especially
because of the dual effects of intrinsic age-related
susceptibility to HFpEF and the expanding older
adult population. The related literature highlights the
high morbidity and mortality associated with HFpEF
(27). The evidence for the beneﬁts of exercise training
in HFpEF is rapidly increasing (28,29), and there
have been many calls for additional exercise-oriented
research (30,31), especially after a succession of
unsuccessful HFpEF pharmacological trials (32,33).
Many conceptualize HFpEF as primarily a disease
of abnormal lusitropic physiology, and assume
that exercise beneﬁts will be manifest principally as
improved diastolic ﬁlling properties (34). However,
seminal research (28) suggests that training beneﬁts
for HFpEF are more likely to be mediated by periph-
eral effects, particularly involving skeletal muscle
quality and intrinsic oxygen utilization. Studies show
increased interstitial fat and relatively reduced aero-
bic (type I) skeletal muscle ﬁbers in HFpEF patients
compared with age-matched controls, suggesting the
potential for their modiﬁcation by exercise (35). Other
studies suggest that at least some HFpEF patients
may achieve central and peripheral vascular bene-
ﬁts (and improved ventricular-vascular coupling)
from exercise training and wellness therapies (36).
Furthermore, HFpEF is particularly associated with
comorbidity (even more than HFrEF) (37), and many
comorbid conditions (e.g., diabetes, peripheral arte-
rial disease, hypertension, CHD) are likely to beneﬁt
from exercise therapy.
Given the evolving perspectives on HFpEF patho-
physiology and steps that can moderate the disease,
further research is essential, including on the utility
of CR. Persistent uncertainties regarding the funda-
mental mechanisms of disease add to the challenge of
meaningful CR trials in terms of patient selection,
type, and intensity of exercise training (38), and
the effectiveness of adjunctive therapies (e.g., diet
and pulmonary pharmacological enhancements, such
as phosphodiesterase inhibitors and possibly even
skeletal muscle enhancements) (39,40).
CR FOR VERY OLD HF PATIENTS. The recently National
Institute on Aging-funded REHAB-HF (Trial of
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Patients) trial (41) will study the utility of exercise
training for older patients with acute decom-
pensated HF including both HFrEF and HFpEF sub-
types, and will particularly target issues salient
to advanced age. The primary outcome measure is
improved physical function, as measured by the short
physical performance battery (42); the secondary
outcome measure is rehospitalization. Other assess-
ments include frailty, multimorbidity, polypharmacy,
and other age-related complexities of care.
CR FOR LVAD PATIENTS. LVAD patients face some
unique barriers to exercise training, including limi-
tations in mobility due to device drive lines and
consoles, as well as dyspnea due to adjacent hemi-
diaphragm compression (43). As the majority of LVAD
patients are currently implanted with continuous-
ﬂow pumps, and many are implanted with concomi-
tant pacemakers, heart rate and ECG often cannot
be used as markers of exercise intensity or safety
(44,45). Furthermore, patients with continuous-ﬂow
LVADs are sensitive to small volume shifts that
signiﬁcantly affect pump ﬂow (46).
The Rehab-VAD (Cardiac Rehabilitation in Patients
With Continuous Flow Left Ventricular Assist De-
vices) trial (47) showed that moderate intensity aer-
obic training yielded signiﬁcantly improved health
status (measured by the Kansas City Cardiomyopathy
Questionnaire), total treadmill time, and leg strength
(measured using an isokinetic dynamometer) in con-
tinuous LVAD patients, but without improvements
in peak VO2. Safety of CR in LVAD patients was sug-
gested by only 1 event (syncope) in over 300 sessions.
ACCOMPLISHING ADHERENCE. The World Health
Organization deﬁnes adherence to long-term therapy
as “the extent to which a person’s behavior—taking
medication, following a diet, and/or executing life-
style changes—corresponds with agreed recommen-
dations from a health care provider” (48). A key
implication is that adherence difﬁculties usually
entail more than 1 barrier, and a single-factor ap-
proach usually achieves only limited effectiveness.
Multiple impediments to exercise adherence
among HFrEF patients have consistently been iden-
tiﬁed (49,50). Patients are generally older and have
age-related limitations, commonly including multi-
morbidity, polypharmacy, disability, frailty, visual
and hearing deﬁcits, incontinence, falls, and cognitive
deﬁcits, all compounding management complexity
and impediments to adherence. HF symptoms, such
as fatigue and dyspnea, may detract from the capacity
of patients to achieve consistent exercise and phy-
sical activity patterns. Recurrent HF exacerbationsand associated comorbidities often precipitate re-
current hospitalizations that lead to more decon-
ditioning, which may hamper ongoing motivation
to resume activities (51). Psychological barriers to
adherence among HF patients are additionally en-
cumbering. Depressive symptoms are found in nearly
30% of patients with HF and are associated with
increased risk of mortality, rehospitalization, and
cardiac events (52).
Tierney et al. (53) focused on exercise adherence
among HF patients and suggests components of social
cognitive theory to reinforce exercise adherence:
1) increase knowledge of the risks and beneﬁts of
exercise; 2) promote self-efﬁcacy and conﬁdence
in being able to perform or control the behavior;
3) promote outcome expectations of the desired out-
comes; and 4) promote facilitators and minimize
barriers to perform the desired behavior.
Supportive practitioners can help by providing
clear information, which in many cases will need to
be repeated frequently. Studies focusing on dietary
interventions for HF highlight a generalizable prob-
lem wherein patients recurrently deny knowing
that healthful recommendations exist (50). Practi-
tioners can also build their patients’ self-conﬁdence
and inclinations for physical activity by accepting
and accommodating their sense of limitations, being
ﬂexible, and encouraging realistic activities and
goals. Overall, behavior change theory constructs
include therapeutic patient-provider communication,
patient engagement in realistic goal setting, self-
monitoring of progress, and mutual problem-solving
to reduce barriers and foster social support.
EXPANDING MODELS OF EXERCISE
ASSESSMENT AND TRAINING TO IMPROVE
CR UTILIZATION AND ADHERENCE
There is emerging evidence on the effectiveness of
complementary or alternative CR models that may be
particularly useful in addressing the adherence chal-
lenges of HF patients. In select populations, home-
based CR has been demonstrated to be as effective
as center-based CR in improving exercise capacity,
risk factor control, and health-related quality of
life (54). Other promising models include inter-
ventions tailored to an individual’s risk proﬁle and
delivered through telehealth, web-based platforms,
and community-based or home-based programs (55).
Structured telephone support and telemonitoring
have been demonstrated to be effective in reducing
the risk of all-cause mortality and HF-hospitalizations
in HFrEF patients, and also in improving quality of
life, reducing costs, and improving evidence-based
CENTRAL ILLUSTRATION Heart Failure and CR: Challenges and Opportunities
Forman, D.E. et al. J Am Coll Cardiol. 2015; 65(24):2652–9.
Cardiac rehabilitation (CR) provides proven beneﬁts for heart failure with reduced ejection fraction patients, particularly functional gains,
improved quality of life, and decreased hospitalizations. Still, key challenges remain: poor adherence, logistical barriers, comorbidity, and
geriatric syndromes are among the impediments that erode CR’s utility in contemporary management. Research is needed to clarify models of
cardiac rehabilitation and exercise training that best surmount these challenges. Research is also essential to clarify the presumed beneﬁts of
CR for heart failure with preserved ejection fraction (HFpEF). LVAD ¼ left ventricular assist device.
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2657prescribing (56). Emerging evidence shows promise in
the feasibility and acceptability of mobile technology
interventions in CR (57). Recently, a mobile care de-
livery platform was integrated within a CR program
and enhanced both patient and physician perceptions
of the CR caregiving process (58).
Whereas CR is now structured as a relatively
formulaic fee-for-service model with speciﬁc criteria
required to document participation and payment, a
recent AHA advisory calls for consideration of new
models of care that achieve more convenient exercise
training and wellness objectives that are more likely
to be successful (59). As models of CR care evolve, it
is incumbent on investigators to prove the efﬁcacy of
new CR models in terms of costs, safety, enrollment,
adherence, and qualitative/quantitative outcomes.
PERTINENT CHANGES IN
U.S. HEALTHCARE DYNAMICS
CR delivery will potentially be transformed in the
greater context of changes in American healthcare.
The Affordable Care Act was initiated in 2010 as a
means to ensure that patients receive high-valuehealthcare that better responds to each individual’s
own sense of priority and wellness (60). Accountable
Care Organizations are models of care fostered by the
Affordable Care Act to facilitate prevention strategies
and treatment that maximize efﬁciencies and value.
As a comprehensive program that fosters more efﬁ-
cacy and quality of care, CR has the potential to
become an effective Accountable Care Organization
instrument (61). CR can be applied to optimize pre-
vention in relation to aggregate risk (including age),
thereby facilitating increased prevention, earlier
mobilization, better transitions of care, and greater
overall value of care. Aligning incentives among
providers and eliminating disincentives to patients
(e.g., copayments) add to the potential for more pa-
tients to enroll and participate in CR, including
women, minorities, the elderly, and those in lower
socioeconomic brackets.
CONCLUSIONS
CR is at a critical juncture. While there is a strong
rationale for exercise and wellness therapy for HFrEF,
persistent underutilization of CR for patients with
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with HFrEF. Major changes in U.S. healthcare are
still evolving that seem likely to shift priorities
and standards towards increased emphasis on CR.
Therefore, the recent decision by CMS to include
HFrEF as an eligible diagnosis for CR payment is
an important step, but only part of the solution
(Central Illustration). Additional insights regarding
the efﬁcacy and dissemination of CR to HFrEF andHFpEF patients of all ages, and related issues of
adherence, safety, efﬁcacy, and ﬁnancial feasibility
are needed to realize CR’s full potential.
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